Mayo Clinic announced today additional capabilities within Mayo Clinic Platform_Orchestrate that make it more efficient for researchers to access standardized, real-world cancer data from Mayo Clinic and participating Mayo Clinic Platform_Connect partners. This gives researchers the ability to generate insights that can accelerate cancer research and improve patient care.
Developing new cancer therapies is a long and complex process that typically takes many years. Orchestrate's capabilities can help shorten this timeline by giving researchers faster access to high-quality, real-world cancer data.
Orchestrate is now using an industry-leading, standardized framework to organize complex cancer information, known as Observational Medical Outcomes Partnership (OMOP) Oncology. The new function can present de-identified data in a consistent, structured and research-ready format. This includes standardized information such as tumor characteristics, biomarkers, staging, treatments, progression and outcomes. These key oncology attributes are refined from a rich background of structured data (e.g., diagnoses, lab test results) and unstructured data (e.g., imaging, pathology and radiology reports) already integrated on Mayo Clinic Platform to enable better clinical insights and research.
The OMOP Oncology model is a product of the global Observational Health Data Sciences and Informatics (OHDSI) initiative. The model's standardized structureallows researchers to analyze complex cancer data more rapidly, accurately and on a larger scale than before.
"The integration of OMOP Oncology into Mayo Clinic Platform has the power to accelerate discovery, improve clinical trial design, unlock real-world insights and support the development of next-generation therapies for patients worldwide," said Elisabeth Heath, M.D., chair of the Department of Oncology at Mayo Clinic.
Nemesis Health, a research and technology service provider for Mayo Clinic Platform, contributed to the development of OMOP Oncology capabilities on Orchestrate.
This year, Mayo Clinic Platform will also incorporate tokenization, a technology that connects de-identified information from across a patient's care experience to provide a more complete, longitudinal view of their healthcare journey. Combined with the OMOP Oncology model, this will give researchers a more comprehensive understanding of a patient's cancer care pathway before, during and after their care at Mayo Clinic.
Launched in 2025, Orchestrate builds on Mayo Clinic Platform's trusted data ecosystem that offers a secure and reliable environment for research and innovation. With these enhanced capabilities, researchers and others seeking to solve healthcare challenges can more easily identify and analyze key groups of people who share common characteristics, understand treatment and outcome patterns, assess the feasibility of clinical trials, and generate real-world evidence to support the development of new cancer therapies.
"Orchestrate strengthens Mayo Clinic's commitment to advancing cancer care through data-driven innovation," says Maneesh Goyal, chief operating officer, Mayo Clinic Platform. "By combining trusted data, advanced artificial intelligence and Mayo Clinic's scientific expertise, these capabilities help unlock deeper insights, accelerate research and ultimately, bring new therapies to patients faster."
To learn more, visit Mayo Clinic Platform_Orchestrate.
